This is a Phase 1 dose-escalation and expansion study that will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of SAIL66 in patients with CLDN6-positive locally advanced or metastatic solid tumors.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
22
SAIL66 as a IV infusion
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States
Georgia Cancer Center at Augusta University
Augusta, Georgia, United States
MUSC Hollings Cancer Center
Charleston, South Carolina, United States
Adverse events of SAIL66[safety and tolerability]
Incidence, nature, and severity of adverse events graded according to NCI Common Terminology CTCAE v5.0, with severity of CRS determined according to the American Society for Transplantation and Cell Therapy (ASTCT) Consensus Grading Criteria
Time frame: From screening until study completion, treatment discontinuation or post-treatment follow up (approximately 18 weeks)
Change from baseline in vital signs[safety and tolerability]
Change from baseline in vital signs
Time frame: From screening until study completion or treatment discontinuation (approximately 18 weeks)
Change from baseline in clinical laboratory test results and examination findings[safety and tolerability]
Change from baseline in clinical laboratory test results and examination findings specified in this study including, but not limited, electrocardiograms (ECGs)
Time frame: From screening until study completion or treatment discontinuation (approximately 18 weeks)
Dose-limiting toxicities (DLTs) of SAIL66[safety and tolerability]
Incidence and nature of the DLTs \[Q3W Dose Escalation part and QW Dose Escalation part\]
Time frame: From Cycle 1 Day 1 until Cycle 1 Day 21 (Cycle 1 is 21 days)
Preliminary anti-tumor activity of SAIL66 when administered at selected dose(s) in each cohort [Expansion part]
Objective response rate (ORR), defined as the proportion of patients with a confirmed complete response (CR) or partial response (PR) on two consecutive occasions \>= 4 weeks apart, assessed per Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 by the investigators.
Time frame: From screening until study completion, treatment discontinuation or post-treatment follow up (approximately 18 weeks)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Tennessee Oncology, PLLC
Nashville, Tennessee, United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
National Cancer Center Hospital East
Kashiwa, Chiba, Japan
National Cancer Center Hospital
Tokyo, Chuo Ku, Japan
Cancer Institute Hospital of JFCR
Tokyo, Koto Ku, Japan
Shizuoka Cancer Center
Shizuoka, Sunto-gun, Japan
Maximum serum concentration (Cmax) of SAIL66 [PK profile]
Maximum serum concentration (Cmax) of SAIL66
Time frame: From screening until study completion, treatment discontinuation or post-treatment follow up (approximately 18 weeks)
Trough serum concentration (Ctrough) of SAIL66 [PK profile]
Trough serum concentration (Ctrough) of SAIL66
Time frame: From screening until study completion, treatment discontinuation or post-treatment follow up (approximately 18 weeks)
Area under the concentration time-curve (AUC) of SAIL66 [PK profile]
Area under the concentration time-curve (AUC) of SAIL66
Time frame: From the first occurrence of CR or PR to progression disease (PD) or death from any cause (whichever occurs first) (approximately 18 weeks)
Objective response rate(ORR)[preliminary efficacy]
ORR assessed per RECIST v.1.1 by the investigators. \[Q3W Dose Escalation part and QW Dose Escalation part\]
Time frame: From screening until study completion, treatment discontinuation or post-treatment follow up (approximately 18 weeks)
Duration of response (DoR)[preliminary efficacy]
Duration of response (DoR), defined as the time from the first occurrence of CR or PR to progression disease (PD) or death from any cause (whichever occurs first), per the investigator according to RECIST v.1.1
Time frame: From the first occurrence of CR or PR to progression disease (PD) or death from any cause (whichever occurs first)(whichever occurs first) (approximately 18 weeks)
Disease control rate (DCR)[preliminary efficacy]
Disease control rate (DCR), defined as the proportion of patients who have CR, PR, or stable disease (SD) as best overall response per RECIST v.1.1 as determined by the investigator. SD must be confirmed at the first tumor assessment as scheduled in Appendix 1 after the start of treatment (the minimum duration for SD).
Time frame: From screening until study completion, treatment discontinuation or post-treatment follow up (approximately 18 weeks)
Progression-free survival (PFS)[preliminary efficacy]
Progression-free survival (PFS), defined as the time from administration of first study treatment to the first occurrence of disease progression or death from any cause, as determined by the investigator according to RECIST v.1.1
Time frame: From administration of first study treatment to the first occurrence of disease progression or death from any cause (approximately 18 weeks)
Overall survival (OS)[preliminary efficacy]
Overall survival (OS), defined as the time from administration of first study treatment to death from any cause \[Expansion part\]
Time frame: From administration of first study treatment to death from any cause (approximately 18 weeks)
Immunogenicity of SAIL66[preliminary efficacy]
Incidence of ADAs to SAIL66 and potential correlation with PK parameters and safety
Time frame: From Cycle 1 Day 1 (Cycle 1 is 21 days) until study completion or treatment discontinuation (approximately 18 weeks)